JGC
GLMD icon

J. Goldman & Co’s Galmed Pharmaceuticals GLMD Stock Holding History

J. Goldman & Co’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-144
Closed -$145K – 390
2018
Q1 		$145K Sell
144
-202
-58% -$294K 0.01% 322
2017
Q4 		$569K Buy
+346
New +$511K 0.03% 263

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

J. Goldman & Co's GLMD Position: Q2 2018 in Review

J. Goldman & Co sold out of Galmed Pharmaceuticals (GLMD) in Q2 2018, closing a stake of 144 shares — an estimated $145K sold.

J. Goldman & Co first reported a position in GLMD in Q4 2017 and held it in 2 quarters. The position peaked at $569K in Q4 2017. 44 funds tracked by Wall St. Rank hold GLMD as of Q2 2018.

  • J. Goldman & Co reported no remaining Galmed Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • J. Goldman & Co sold 144 Galmed Pharmaceuticals shares in Q2 2018, an estimated $145K.
  • J. Goldman & Co first reported a position in Galmed Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • J. Goldman & Co's Galmed Pharmaceuticals position peaked at $569K in Q4 2017.
  • 44 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2018.

Based on J. Goldman & Co's 13F filing for Q2 2018, filed 14 Aug 2018.